|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng
J and Fan S: The roles of tumor-derived exosomes in non-small cell
lung cancer and their clinical implications. J Exp Clin Cancer Res.
37:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Little AG, Gay EG, Gaspar LE and Stewart
AK: National survey of non-small cell lung cancer in the United
States: Epidemiology, pathology and patterns of care. Lung Cancer.
57:253–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gadgeel SM, Stevenson JP, Langer CJ,
Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R,
Yang JC, et al: Pembrolizumab and platinum-based chemotherapy as
first-line therapy for advanced non-small-cell lung cancer: Phase 1
cohorts from the KEYNOTE-021 study. Lung Cancer. 125:273–281. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han JY, Hong EK, Choi BG, Park JN, Kim KW,
Kang JH, Jin JY, Park SY, Hong YS and Lee KS: Death receptor 5 and
Bcl-2 protein expression as predictors of tumor response to
gemcitabine and cisplatin in patients with advanced non-small-cell
lung cancer. Med Oncol. 20:355–362. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Houghton JA: Apoptosis and drug response.
Curr Opin Oncol. 11:475–481. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walczak H, Degli-Esposti MA, Johnson RS,
Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA,
Smith CA, et al: TRAIL-R2: A novel apoptosis-mediating receptor for
TRAIL. EMBO J. 16:5386–5397. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sheridan JP, Marsters SA, Pitti RM, Gurney
A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood
WI, et al: Control of TRAIL-induced apoptosis by a family of
signaling and decoy receptors. Science. 277:818–821. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chinnaiyan AM, O'Rourke K, Tewari M and
Dixit VM: FADD, a novel death domain-containing protein, interacts
with the death domain of fas and initiates apoptosis. Cell.
81:505–512. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bodmer JL, Holler N, Reynard S,
Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J: TRAIL
receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell
Biol. 2:241–243. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ashkenazi A: Targeting the extrinsic
apoptosis pathway in cancer. Cytokine Growth Factor Rev.
19:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li FY, Jeffrey PD, Yu JW and Shi Y:
Crystal structure of a viral FLIP: Insights into FLIP-mediated
inhibition of death receptor signaling. J Biol Chem. 281:2960–2968.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang JK: FLIP as an anti-cancer
therapeutic target. Yonsei Med J. 49:19–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Golks A, Brenner D, Fritsch C, Krammer PH
and Lavrik IN: c-FLIPR, a new regulator of death receptor-induced
apoptosis. J Biol Chem. 280:14507–14513. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
French LE and Tschopp J: Defective death
receptor signaling as a cause of tumor immune escape. Semin Cancer
Biol. 12:51–55. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wen Q, Wang W, Luo J, Chu S, Chen L, Xu L,
Zang H, Alnemah MM, Ma J and Fan S: CGP57380 enhances efficacy of
RAD001 in non-small cell lung cancer through abrogating mTOR
inhibition-induced phosphorylation of eIF4E and activating
mitochondrial apoptotic pathway. Oncotarget. 7:27787–27801. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY,
Zhang WL, Tan C, Li XL, Shen SR, Zhou M, et al: Differential
expression of Epstein-Barr virus-encoded RNA and several
tumor-related genes in various types of nasopharyngeal epithelial
lesions and nasopharyngeal carcinoma using tissue microarray
analysis. Hum Pathol. 37:593–605. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J, Wen Q, Xu L, Wang W, Luo J, Chu S,
Xie G, Shi L, Huang D, Li J and Fan S: Fatty acid
synthase-associated protein with death domain: A prognostic factor
for survival in patients with nasopharyngeal carcinoma. Hum Pathol.
45:2447–2452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng J, Li J, Xu L, Xie G, Wen Q, Luo J,
Li D, Huang D and Fan S: Phosphorylated Mnk1 and eIF4E are
associated with lymph node metastasis and poor prognosis of
nasopharyngeal carcinoma. PLoS One. 9:e892202014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leithner K, Stacher E, Wurm R, Ploner F,
Quehenberger F, Wohlkoenig C, Bálint Z, Polachova J, Olschewski A,
Samonigg H, et al: Nuclear and cytoplasmic death receptor 5 as
prognostic factors in patients with non-small cell lung cancer
treated with chemotherapy. Lung Cancer. 65:98–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daniels RA, Turley H, Kimberley FC, Liu
XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F and
Screaton GR: Expression of TRAIL and TRAIL receptors in normal and
malignant tissues. Cell Res. 15:430–438. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hutchinson RA, Coleman HG, Gately K, Young
V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne
S, et al: IHC-based subcellular quantification provides new
insights into prognostic relevance of FLIP and procaspase-8 in
non-small-cell lung cancer. Cell Death Discov. 3:170502017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koornstra JJ, Kleibeuker JH, van Geelen
CM, Rijcken FE, Hollema H, de Vries EG and de Jong S: Expression of
TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in
normal colonic mucosa, adenomas, and carcinomas. J Pathol.
200:327–335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ozawa F, Friess H, Kleeff J, Xu ZW,
Zimmermann A, Sheikh MS and Büchler MW: Effects and expression of
TRAIL and its apoptosis-promoting receptors in human pancreatic
cancer. Cancer Lett. 163:71–81. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McCarthy MM, Sznol M, DiVito KA, Camp RL,
Rimm DL and Kluger HM: Evaluating the expression and prognostic
value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res.
11:5188–5194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Korkolopoulou P, Saetta AA, Levidou G,
Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K,
Michalopoulos NV, Apostolikas N, et al: c-FLIP expression in
colorectal carcinomas: Association with Fas/FasL expression and
prognostic implications. Histopathology. 51:150–156. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang W, Wang S, Song X, Sima N, Xu X, Luo
A, Chen G, Deng D, Xu Q, Meng L, et al: The relationship between
c-FLIP expression and human papillomavirus E2 gene disruption in
cervical carcinogenesis. Gynecol Oncol. 105:571–577. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Zhang XD, Thompson JF, Screaton G and Hersey P: Progression in
melanoma is associated with decreased expression of death receptors
for tumor necrosis factor-related apoptosis-inducing ligand. Hum
Pathol. 37:1286–1294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Spierings DC, de Vries EG, Timens W, Groen
HJ, Boezen HM and de Jong S: Expression of TRAIL and TRAIL death
receptors in stage III non-small cell lung cancer tumors. Clin
Cancer Res. 9:3397–3405. 2003.PubMed/NCBI
|
|
37
|
Day TW, Najafi F, Wu CH and Safa AR:
Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for
taxol-induced apoptosis. Biochem Pharmacol. 71:1551–1561. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim S, Lee TJ, Park JW and Kwon TK:
Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis
through enhanced XIAP stability and Akt activation in human renal
cancer cells. J Cell Biochem. 105:971–979. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jani TS, DeVecchio J, Mazumdar T, Agyeman
A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine
is cytotoxic to human colon carcinoma cell lines and is synergistic
in combination with tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem.
285:19162–19172. 2010. View Article : Google Scholar : PubMed/NCBI
|
